367 related articles for article (PubMed ID: 34213480)
1. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
3. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
5. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
[TBL] [Abstract][Full Text] [Related]
7. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A
Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
9. The role of hydroxyurea in the management of sickle cell disease.
Davies SC; Gilmore A
Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
[TBL] [Abstract][Full Text] [Related]
11. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
[TBL] [Abstract][Full Text] [Related]
12. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
14. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
16. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
[TBL] [Abstract][Full Text] [Related]
17. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
18. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
Barbu EA; Dominical VM; Mendelsohn L; Thein SL
PLoS One; 2019; 14(12):e0226583. PubMed ID: 31869367
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.
Adewoyin AS; Oghuvwu OS; Awodu OA
Afr Health Sci; 2017 Mar; 17(1):255-261. PubMed ID: 29026400
[TBL] [Abstract][Full Text] [Related]
20. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.
Haywood C; Beach MC; Bediako S; Carroll CP; Lattimer L; Jarrett D; Lanzkron S
Am J Hematol; 2011 Jan; 86(1):85-7. PubMed ID: 21117058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
